Start investing in yourself
Tirzepatide is a groundbreaking therapy that functions as a dual GIP and GLP-1 receptor agonist. It mimics the actions of both incretin hormones, enhancing glucose-dependent insulin secretion by the pancreatic beta cells, thereby regulating blood glucose levels. Furthermore, Tirzepatide slows down gastric emptying and suppresses appetite, contributing to weight loss, a significant benefit for patients with type 2 diabetes. Thus, this promising therapy addresses both hyperglycemia and obesity, typical in many diabetics.
Both tirzepatide (Mounjaro®) and semaglutide (Ozempic®, Wegovy®) exhibit promising results in improving metabolic health, reducing hemoglobin A1C (hbA1C) levels, and aiding in weight loss. Furthermore, data suggests that these drugs may decrease the risk of cardiovascular events such as heart attacks or strokes and enhance cardiovascular outcomes.
Semaglutide Therapy is FDA-approved weight loss medication therapies. The medications are administered once weekly via subcutaneous injection and produce an average weight loss of 50 lb over 6 months of treatment. It belongs to a class of drugs called GLP-1 receptor agonists, which work by increasing insulin release and reducing glucose production in the liver
The specific dosages vary, and it is important for individuals to adhere strictly to Dr. Tolman's prescribed instructions for optimal and safe results.
Foods to Avoid:
Stay Informed
C. JONES
J. MILER
L. DRIPER
All Rights Reserved NSI
Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice. The information contained herein is not intended to diagnose, treat, cure or prevent any disease.